Association of serum osteoprotegerin with ankle-brachial index and urine albumin: Creatinine ratio in African-Americans and non-Hispanic whites

Atherosclerosis

Volumn 206, Issue 2, 2009, Pages 575-580

  Ali, Zeenat ^a   Ellington, Allison A ^a   Mosley Jr , Thomas H ^b   Kullo, Iftikhar J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Ankle brachial index; Osteoprotegerin; Peripheral arterial disease (PAD)

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; OSTEOPROTEGERIN;

ADULT; AFRICAN AMERICAN; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RISK ASSESSMENT; RISK FACTOR;

AFRICAN AMERICANS; AGED; ALBUMINURIA; ANKLE BRACHIAL INDEX; C-REACTIVE PROTEIN; COHORT STUDIES; CREATININE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OSTEOPROTEGERIN; REGRESSION ANALYSIS;

EID: 70349429734     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.03.032     Document Type: Article

References (58)

1. Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 (1998) 14363-14367
2. Schoppet M., Preissner K.T., and Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arteriosc Thromb Vasc Biol 22 (2002) 549-553
3. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
4. Min H., Morony S., Sarosi I., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192 (2000) 463-474
5. Dhore C.R., Cleutjens J.P., Lutgens E., et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21 (2001) 1998-2003
6. Sandberg W.J., Yndestad A., Oie E., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26 (2006) 857-863
7. Rhee E.J., Lee W.Y., Kim S.Y., et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci 108 (2005) 237-243
8. Anand D.V., Lahiri A., Lim E., et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47 (2006) 1850-1857
9. Browner W.S., Lui L.Y., and Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86 (2001) 631-637
10. Kim S.M., Lee J., Ryu O.H., et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf) 63 (2005) 594-598
11. Gannage-Yared M.H., Fares F., Semaan M., et al. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol 64 (2006) 652-658
12. Jono S., Ikari Y., Shioi A., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106 (2002) 1192-1194
13. Schoppet M., Sattler A.M., Schaefer J.R., et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88 (2003) 1024-1028
14. Palazzuoli A, Ascione R, GallottaM et al. Osteoprotegerin and B-type natriuretic peptide in acute coronary syndromes with preserved systolic function: relation to coronary artery disease extension. Int J Cardiol 2008, Aug 15, in press doi:10.1016/j.ijcard.2008.05.048.
15. Crisafulli A., Micari A., Altavilla D., et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 109 (2005) 389-395
16. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 2175-2180
17. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51 (2008) 627-633
18. Murabito J.M., Evans J.C., Larson M.G., et al. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med 163 (2003) 1939-1942
19. Newman A.B., Shemanski L., Manolio T.A., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 538-545
20. Lee A.J., Price J.F., Russell M.J., et al. Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study. Circulation 110 (2004) 3075-3080
21. Yudkin J.S., Forrest R.D., and Jackson C.A. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 2 (1988) 530-533
22. Nakamura S., Kawano Y., Inenaga T., et al. Microalbuminuria and cardiovascular events in elderly hypertensive patients without previous cardiovascular complications. Hypertens Res 26 (2003) 603-608
23. Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S., et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19 (1999) 1992-1997
24. Campese V.M., Bianchi S., and Bigazzi R. Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension?. Curr Opin Nephrol Hypertens 9 (2000) 143-147
25. Granger C.B., Van Eyk J.E., Mockrin S.C., et al. National heart, lung, and blood institute clinical proteomics working group report. Circulation 109 (2004) 1697-1703
26. Boerwinkle E. Multi-center genetic study of hypertension: the Family Blood Pressure Program (FBPP). Hypertension 39 (2002) 3-9
27. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344 (2001) 1608-1621
28. Zeger S.L., and Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42 (1986) 121-130
29. Siepi D., Marchesi S., Vaudo G., et al. Preclinical vascular damage in white postmenopausal women: the relevance of osteoprotegerin. Metab Clin Exp 57 (2008) 321-325
30. Abedin M., Omland T., Ueland T., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 99 (2007) 513-518
31. Avignon A., Sultan A., Piot C., et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 28 (2005) 2176-2180
32. Golledge J., McCann M., Mangan S., et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35 (2004) 1636-1641
33. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 44 (2004) 1970-1976
34. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
35. Hofbauer L.C., Khosla S., Dunstan C.R., et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15 (2000) 2-12
36. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
37. Yano K., Tsuda E., Washida N., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14 (1999) 518-527
38. Khosla S., Arrighi H.M., Melton III L.J., et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13 (2002) 394-399
39. Szulc P., Hofbauer L.C., Heufelder A.E., et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86 (2001) 3162-3165
40. Price P.A., June H.H., Buckley J.R., et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21 (2001) 1610-1616
41. van der Klift M., Pols H.A., Hak A.E., et al. Bone mineral density and the risk of peripheral arterial disease: the Rotterdam Study. Calcif Tissue Int 70 (2002) 443-449
42. Barengolts E.I., Berman M., Kukreja S.C., et al. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 62 (1998) 209-213
43. Hak A.E., Pols H.A., van Hemert A.M., et al. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 20 (2000) 1926-1931
44. Pennisi P., Signorelli S.S., Riccobene S., et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 15 (2004) 389-395
45. Sattler A.M., Schoppet M., Schaefer J.R., et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 74 (2004) 103-106
46. Hofbauer L.C., and Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification?. Lancet 358 (2001) 257-259
47. Ziegler S., Kudlacek S., Luger A., et al. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182 (2005) 175-180
48. Murabito J.M., Keyes M.J., Guo C.Y., et al. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: the Framingham Offspring Study. Atherosclerosis 203 (2009) 509-514
49. Pedrinelli R., Giampietro O., Carmassi F., et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 344 (1994) 14-18
50. Stehouwer C.D. Heterogeneity of the association between plasma homocysteine and atherothrombotic disease: insights from studies of vascular structure and function. Clin Chem Lab Med 39 (2001) 705-709
51. Knudsen S.T., Foss C.H., Poulsen P.L., et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 149 (2003) 39-42
52. Kazama J.J., Shigematsu T., Yano K., et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39 (2002) 525-532
53. Rasmussen L.M., Tarnow L., Hansen T.K., et al. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 154 (2006) 75-81
54. Collin-Osdoby P., Rothe L., Anderson F., et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276 (2001) 20659-20672
55. Hofbauer L.C., Shui C., Riggs B.L., et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 280 (2001) 334-339
56. Pritzker L.B., Scatena M., and Giachelli C.M. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15 (2004) 2834-2841
57. Malyankar U.M., Scatena M., Suchland K.L., et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 275 (2000) 20959-20962
58. Bennett B.J., Scatena M., Kirk E.A., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 26 (2006) 2117-2124